PFE - Pfizer Inc.
| Previous close | 38.19 |
| Open | 35.50 |
| Bid | 35.31 x 4000 |
| Ask | 35.32 x 4000 |
| Day's range | 34.91 - 35.73 |
| 52-week range | 27.88 - 44.56 |
| Volume | 48,850,404 |
| Avg. volume | 30,536,612 |
| Market cap | 196.697B |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | 12.65 |
| EPS (TTM) | 2.80 |
| Earnings date | 27 Jul 2020 - 31 Jul 2020 |
| Forward dividend & yield | 1.52 (3.98%) |
| Ex-dividend date | 07 May 2020 |
| 1y target est | 41.36 |
- Reuters
Pfizer declines about 8% after setback to breast cancer treatment
The treatment, Ibrance, was being tested along with the standard of care for early breast cancer in men and women, against standard of care alone, the company said on Friday. The study was broadly seen to have a high probability of success readout, but the early failure represents a meaningful setback for Pfizer, JP Morgan analysts said in a note, cutting its price target on the stock by $1 to $37.
- Zacks
Pfizer's Ibrance Fails in Phase III Early Breast Cancer Study
Pfizer's (PFE) phase III PALLAS study compared Ibrance plus standard adjuvant endocrine therapy to standard adjuvant endocrine therapy in HR+, HER2- early breast cancer.
- Zacks
5 Dogs of the Dow for the Month of June
Dogs of the Dow have large customer base, sustainable business model, a long track of profitability and strong liquidity, which allow them to offer sizable yields regardless of market conditions.
- Zacks
Drugmakers Focus on Coronavirus Vaccine by 2020: 4 Winners
Clinical trials of non-COVID-19 drugs have taken a backseat as most drugmakers and biotechnology companies are speeding up development of a vaccine for the novel coronavirus.
- Bloomberg
Cancer Summit Presses Toward Treatments in Covid’s Shadow
(Bloomberg) -- The year’s biggest meeting of cancer researchers was subjected to a coronavirus overhaul this year, but even in scaled-back form it forced investors to recalibrate their expectations for some closely watched medicines.The American Society of Clinical Oncology meeting is the field’s most important gathering each spring, providing a stage for major pharmaceutical companies to unveil major findings and tout promising treatments. It’s also an annual opportunity for all kinds of researchers, doctors, executives and investors to rub elbows.With Covid-19 making travel uncomfortable and splashy conferences impossible this year, the summit was mostly a virtual affair. Still, it delivered many of the kinds of important victories and stinging setbacks it often does. And the meeting showed that even as the drug industry races to identify virus treatments and vaccines, cancer remains perhaps its most important business overall.“When the coronavirus wanes and we have a vaccine, and this infectious disease is brought under control, we will still have cancer and the need for new treatments,” said Richard Schilsky, ASCO’s chief medical officer, in an interview. “We have millions of patients around the world who need new and improved treatments for cancer.”Among the most noteworthy winners was U.K. pharmaceutical giant AstraZeneca Plc, which reported that its blockbuster Tagrisso reduced the risk of dying from lung cancer or relapse by four-fifths over three years. The drug is already AstraZeneca’s biggest product, bringing in $982 million in sales in the first quarter alone.Some smaller drug companies also logged what looked like significant victories: Trillium Therapeutics Inc. said that a second patient taking its experimental lymphoma therapy responded to the treatment. Shares of Trillium, which has a market value of about $560 million, surged more than 17% on FridayAnd as ASCO played out, other big cancer-research news also roiled drugmaker stocks.Pfizer Inc. shares fell 5.1% in trading before U.S. exchanges opened Monday after the U.S. drug bellwether said a late-stage study of its treatment for metastatic breast cancer, Ibrance, was unlikely to show a statistically significant improvement in invasive disease-free survival for patients with early breast cancer.Though the Covid-19 pandemic has been the defining story of the health-care business this year, the ASCO meeting was a reminder that most of the world’s pharmaceutical companies remain keenly focused on finding new cancer treatments to generate profits. And that focus has paid off for patients: The U.S. death rate from cancer has been falling at a record pace, thanks largely to big advances in treating lung tumors.Data presented at the meeting showed progress in combating the second leading cause of death worldwide, Schilsky said. Researchers found medicines used for patients with advanced disease can have an even bigger benefit for those with recently diagnosed tumors, while medicines are emerging that are effective against a wide range of tumors that are driven by specific gene mutations.Deals Getting DoneLarge drugmakers have remained on the prowl for promising cancer therapies that they can acquire through mergers or other transactions. Even Gilead Sciences Inc., which has been in the headlines because of its potential coronavirus treatment remdesivir, has been getting cancer-focused deals done against the backdrop of the pandemic.Last week, Gilead agreed to work on immunotherapy drugs with biotech Arcus Biosciences Inc. And earlier this year it agreed to buy cancer-drug maker Forty Seven for $4.9 billion. Gilead has been pressured by investors to find new drugs that can take the place of some of its aging blockbusters. It made another big bet on cancer when it bought Kite Pharma and its drug Yescarta, though sales of the highly priced genetic therapy have so far failed to live up to expectations.At ASCO, Gilead presented encouraging new data on magrolimab, an immunology drug that was developed by Forty Seven, a sign that the company’s wager could pay off. Gilead’s management is successfully building a pipeline of potential new therapies, Jefferies & Co. analyst Michael Yee said in a note sent to clients.Gilead shares dropped 1.5% early Monday. They now have gained about 20% so far this year, in part because of excitement over remdesivir.Breakthroughs at ASCO could make smaller companies enticing to Gilead and to other giants looking to add to their rosters of experimental therapies. Adaptimmune Therapeutics Plc’s U.S.-traded shares more than doubled in value after the company presented early studies for therapies that could treat a number of cancers, including lung and head and neck tumors.Allogene Therapeutics Inc., which is developing a CAR-T therapy similar to Yescarta, gained 3.5% Friday after it said its treatment benefited 63% of patients with blood cancer in an early-stage trial. Allogene’s founders ran Kite Pharma before selling it to Gilead for $11 billion in 2017.Dueling GiantsLike Gilead, Bristol-Myers Squibb Co. has also sought to refashion itself into a cancer-fighting juggernaut, mostly notably with its $74 billion takeover of Celgene Corp. last year. Even before that transaction, the company was locked in a battle with rival Merck & Co. for supremacy in the market for lung-cancer immunotherapies.Merck’s Keytruda and Bristol-Myers’s Opdivo are blockbusters for each company, and the drugmakers have raced to expand their use in a range of tumor types. But at ASCO, a study of Opdivo in combination with another Bristol-Myers drug, Yervoy, supported what JPMorgan Chase & Co. analyst Chris Schott said in a note was a “niche role” in treating certain lung-cancer patients -- not one that will upset Keytruda’s dominance.Bristol-Myers shares declined 0.2% on Friday, while Merck advanced 2.1%. Both were little changed before U.S. markets opened Monday.Last year, Opdivo generated $7.2 billion in revenue for Bristol-Myers, while Yervoy brought in $1.5 billion. Together, the two drugs accounted for roughly a third of the company’s sales. Meanwhile, Keytruda generated $11 billion for Merck, about 24% of its sales.Another challenge to Keytruda may come from Switzerland’s cancer titan Roche Holding AG. The drugmaker presented data at ASCO showing that combining the experimental tiragolumab with one of its proven medicines, Tecentriq, worked better than prescribing Tecentriq alone in patients with metastatic non-small-cell lung cancer. The phase 2 data suggests it “could potentially compete with Merck’s Keytruda in a segment of lung-cancer patients,” wrote Cinney Zhang of Bloomberg Intelligence.Some Chinese drugmakers also showed promising findings in liver cancer. A combination from Innovent Biologics Inc. showed initial efficacy comparable to Roche in hepatocellular carcinoma, for which China accounts for almost than half of new cases. Innovent shares surged 10% in Hong Kong trading Monday.(Updates with share moves for Pfizer, Gilead and Innovent in eighth, 14th and last paragraphs)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- Motley Fool
Pfizer Breast Cancer Drug Posts "Disappointing" Results in Clinical Trials
One of Pfizer's (NYSE: PFE) blockbuster drugs has effectively flopped in a late-stage combination therapy trial. The company announced on Friday that the results of a Phase 3 trial for its Ibrance (Palbociclib) breast cancer drug in the treatment of early stage breast cancer were disappointing. The results of the study indicate that, when used in combination with post-surgery endocrine therapy, it "is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival (iDFS)."
- Motley Fool
Is Pfizer a Great Dividend Stock?
While not entirely recession-proof, pharmaceutical companies can weather the storm better than many companies in other industries. Only Johnson & Johnson and Swiss-based Roche Holdings have larger market capitalizations. When it comes to dividend yield, Pfizer takes third place on the podium again.
- Business Wire
Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer
As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. (NYSE: PFE) reports that following a preplanned efficacy and futility analysis, the independent Data Monitoring Committee (DMC) of the collaborative Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study (PALLAS) determined that the trial is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival (iDFS). Patients currently receiving palbociclib in the study will be advised about next steps by their physicians and long-term follow up of all patients will proceed as planned. No unexpected new safety signals were observed in patients receiving palbociclib.
- Zacks
4 Stocks to Watch as Dow Breezes Past 25,000 Points
Dow Jones' journey past 25,000 points this week could mark the beginning of a series of gains ahead, owing to some major tailwinds.
- Yahoo Finance
ER doctor: 12-18 month coronavirus vaccine timeline 'is extremely optimistic'
As the fallout from the coronavirus pandemic continues, the search for a vaccine is not slowing down.
- Zacks
Pfizer (PFE) Down 1.9% Since Last Earnings Report: Can It Rebound?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology
The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology
- Zacks
Merck Inks 3 Deals for Coronavirus Anti-infective & Vaccines
Merck (MRK) to buy Themis, which is making a COVID-19 vaccine. It is also buying global rights to a private biotech's antiviral candidate, EIDD-2801, which is in early clinical studies to treat COVID-19.
- Yahoo Finance
Coronavirus update: Novavax begins vaccine trials; Brazil reports second-highest number of cases in world
Novavax announced it would begin human trials for its coronavirus vaccine, while COVID-19 engulfs Brazil.
- Yahoo Finance
Novavax expects COVID-19 vaccine trial results in July
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
- Zacks
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
- Zacks
Coronavirus Vaccine Efforts Continue, Novavax Begins Human Trial
As several pharma/biotech companies speed up efforts to make a vaccine for COVID-19, Novavax (NVAX) begins human testing of its candidate, NVX-CoV2373.
- Yahoo Finance
An 'unprecedented' effort to find a coronavirus vaccine has over 100 horses in the race
Vaccines are perceived as key to ending the restraints on work and life that have decimated the global economy, and returning to some sense of normalcy.
- Motley Fool
3 Large-Cap Coronavirus Stocks Still Worth Buying
Abbott Labs (NYSE: ABT) made headlines in late March when the FDA gave emergency use authorization (EUA) for the company's COVID-19 test that runs on its ID NOW platform. Abbott also announced interim results last week from a clinical study in urgent care clinics that showed high levels of sensitivity for positive results and specificity for negative results.
- Yahoo Finance UK
Coronavirus: AstraZeneca boss confident Covid-19 vaccine can succeed
The drug giant has teamed up with Oxford University to provide millions of doses should the clinical trials work.
- Yahoo Finance
Some wellness products growing ‘over 1,000%’ during pandemic: Ro CEO
The coronavirus pandemic accelerated a wellness renaissance among consumers as shelter in place orders took effect, based on some of the sales trends seen by companies including Ro.
- Business Wire
Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC
Pfizer Inc. (NYSE: PFE) today announced that it and Wyeth recommend rejection of the unsolicited tender offer made by Huguenot Bond Liquidity, LLC ("Offeror") on May 11, 2020 (as amended and restated on May 21, 2020) to purchase up to $162.5 million principal amount of Pfizer’s outstanding 7.200% notes due 2039 (the "Pfizer Notes") and up to $130.0 million principal amount of Wyeth’s 5.950% notes due 2037 (the "Wyeth Notes" and together with the Pfizer Notes, the "Notes"). Wyeth is a wholly-owned subsidiary of Pfizer. Pfizer and Wyeth do not endorse Offeror’s unsolicited tender offer, and neither Pfizer nor Wyeth is affiliated or associated with the Offeror, the tender offer or the offer documentation. The Offeror did not inform Pfizer of the tender offer, and Pfizer only became aware of the offer through a third party source. Further, there is no disclosure of information regarding the Offeror or any indication as to a source of financing for the offer in the offer documentation.
- Zacks
Is Pfizer (PFE) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Yahoo Finance
Telehealth is going to 'become the default' for patients: Ro CEO
Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.
- Yahoo Finance
The race for a coronavirus treatment is fanning fears of 'vaccine nationalism'
Geopolitical rivalries, as well as practical considerations, are emerging as real hurdles in the race for a COVID treatment.
